Novavax surges 10% after it begins phase 3 trial of COVID-19 vaccine
In the scenario that Novavax succeeds in developing a successful COVID-19 vaccine candidate, it is at the ready to produce billions of doses.
Full Article
Novavax surges 10% after it begins phase 3 trial of COVID-19 vaccine
Business Insider
0 shares
1 views
You might like
Related news coverage
Stock Alert: CureVac Up 6% After Initiating Phase 2 Trial Of COVID-19 Vaccine
RTTNews
Shares of CureVac N.V. (CVAC) are gaining over 6% on Wednesday morning. Tuesday after the bell, CureVac announced that it has..
-
GNFT Soars On LabCorp Deal, INO's COVID-19 Vaccine Trial On Partial Hold, FDA Expands Xeljanz Label
RTTNews
-
Dow ends 400+ points up in reversal of last week's selloff
Proactive Investors
-
Wall Street looking strong to open the week
Proactive Investors
-
Wall Street rises at the opening bell
Proactive Investors
Advertisement
More coverage
Stock Alert: Inovio Pharma Plummets 30% As FDA Puts On Hold Its Coronavirus Vaccine
RTTNews
Shares of Inovio Pharmaceuticals, Inc. (INO) tanked 30% on Monday morning after the biotechnology company announced that phase 2/3..
-
Novavax to present on COVID-19 vaccine candidate this week
Proactive Investors
-
Inovio stock plunges more than 34% as FDA puts Covid-19 vaccine trial on hold
bizjournals
-
Mumbai: Clinical trial of COVID-19 vaccine begins at KEM, Nair hospitals
Mid-Day
-
Nasdaq Jumps Despite Costco Pullback; Novavax Starts Vaccine Phase 3 Trial
Motley Fool